Can a pill target multiple Hard-to-Treat cancers?

NCT ID NCT07755397

Recruiting now Disease control Sponsor: Jubilant Therapeutics India Limited Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental pill called JBI-778 in people with certain advanced cancers: EGFR-mutated lung cancer (with or without brain metastases), recurrent high-grade glioma, or adenoid cystic carcinoma. The drug is designed to block a protein that helps cancer cells grow. The study aims to find a safe dose and see how the body processes the drug, while also checking for any signs that it shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JBI-778, an oral PRMT5 inhibitor taken as capsules once daily
What this could lead to: If successful, this could lead to a new targeted treatment option for certain hard-to-treat cancers, including lung cancer with brain metastases and recurrent glioma.
What could go wrong: This is an early-phase, first-in-human trial with a small number of participants, so safety and effectiveness are not yet established. The drug may cause side effects or may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoid cystic carcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOID CYSTIC CARCINOMA METASTATIC ADENOID CYSTIC CARCINOMA OF THE HEAD AND NECK NSCLC PATIENTS WITH EGFR ACTIVATING MUTATION

Contacts and locations

Locations

All India Institute of Medical Sciences(AIIMS)
RECRUITING

New Delhi, National Capital Territory of Delhi, 110029, India
HCG Manavata Cancer Centre
RECRUITING

Nashik, Maharashtra, 422002, India
Kiran Super Multi-Speciality Hospital
RECRUITING

Surat, Gujarat, 395004, India
Oncoville Cancer Hospital and Research Center
RECRUITING

Bangalore, Karnataka, 560072, India
SunAct Cancer Institute Pvt Ltd
RECRUITING

Thane, Maharashtra, 400615, India
Tata Memorial Center
RECRUITING

Mumbai, Maharashtra, 400012, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.